News 1+1丨The "China Speed" of Vaccination
There have been 420 million doses of vaccination nationwide.
As of 9 o'clock on May 18, the coverage rate of the "first dose" of the new crown vaccine for people aged 18 and above in Beijing exceeded 80%. Affected by the epidemic, the number of daily vaccinations in Hefei, Anhui increased significantly.
Can the occurrence of this local local epidemic promote nationwide vaccination?
From a global perspective, what role is China's vaccine playing?
After the outbreak, the amount of vaccination increased, can the vaccine supply keep up?
Shao Yiming, a researcher at the Chinese Center for Disease Control
and Prevention and a
member of the expert team for vaccine research and development of the scientific research team:
indeed this is an important issue. Our country’s vaccine supply is gradually increasing according to our needs for epidemic prevention and control. For vaccination.
Of course, we do not want to see where vaccination lags behind the national level. This should be avoided.
But we said everyone should be nervous, but don't panic.
Our supply of vaccines is sufficient, and the release of our production capacity is gradually accelerating.
Under this circumstance, everyone has enough vaccines to vaccinate, and our potential for vaccinations is great. We say that twelve million has set a world record, but as long as we have demand, the daily vaccination volume can reach More than 20 million.
What reminder did the five experts who went to Vietnam get to the Indian mutant virus to remind us?
Shao Yiming, a researcher at the Chinese Center for Disease Control
and Prevention and a
member of the Vaccine R&D Expert Team of the Scientific Research Team:
We say that prevention and control must be active, that is, no measures can be relaxed until the global epidemic is significantly reduced and improved.
We have seen that some countries are too optimistic, celebrating their victory in prevention and control prematurely, slackening their public health measures, and vaccination has not progressed smoothly, which has caused the current spread and expansion of the Asian epidemic. .
This kind of lessons actually happened in many countries last year, so we must learn from these lessons and put our domestic work on the basis of doing a very good job, just like our country’s deployment of external defense imports and internal defense rebounds. , This job can't relax at all.
Domestic inactivated vaccines are still effective against most mutant strains
Shao Yiming, a researcher at the Chinese Center for Disease Control and Prevention, and a member of the Vaccine R&D Expert Team of the Scientific Research Group:
I want to explain a concept. We are referring to the genetic level of virus mutation.
The mutation at the gene level will continue to occur, and it will increase, but the slight mutation at the gene level does not necessarily cause what we call phenotype, which is the epidemic characteristics of the virus, the severity of the virus's disease, and whether the virus is Escape the monitoring of vaccines, these phenotypic changes are relatively slow, so we can see from the existing major strains of high concern that the British strain has no problems. The protection of the existing vaccines has no impact at all. No, and South Africa and Brazil will have a greater impact than the British strain, but from the existing, whether it is the mRNA vaccine in the United States or the inactivated vaccine in our country, the large-scale and large-scale population in the real world In the study, it was effective. The Indian strain appeared relatively late, but judging from the number of its mutations, it did not surpass the Brazilian and South African strains.
Therefore, Indian scientists have also done some tests and believe that the inactivated and viral vector vaccines currently used in India are still effective, but we cannot relax our vigilance. The monitoring must be continued, and our people can also rest assured that the relevant state departments and prevention and control The system is closely tracking this information, and once there is, we are able to deal with mutant strains.
According to the fastest rate of vaccination, experts: the herd immunity barrier is expected to be achieved within the year
Shao Yiming, a researcher at the Chinese Center for Disease Control and
Prevention and a
member of the Vaccine R&D Expert Team of the Scientific Research Team: In terms of
speed, we are divided into two types of areas. One is the key prevention and control areas, and the key prevention and control areas. We have seen that one after another, and some have been achieved. Some are close to realization.
In our epidemic prevention pressure is not great, such as inland areas with less international exchanges, it is also progressing in an orderly manner.
As we reach the middle of the year, especially in the second half of the year, after the huge increase in production capacity, we will increase the rate of vaccination. I believe that within the year we will be able to achieve the goal of establishing a herd immunity barrier.
The infection rate of a small town in Brazil dropped by 75% after being vaccinated with the Chinese new crown vaccine
Shao Yiming, a researcher of the Chinese Center for Disease Control
and Prevention and a
member of the expert group of vaccine research and development team of the scientific research team:
Because the infection rate decreases after vaccination, it must be the preventive effect of the vaccine.
Our country’s vaccine is in many countries, and people in more than 80 countries are using our country’s vaccine. China’s vaccine is truly a global public product as announced by our leaders to the world. It not only supports China’s new crown Prevention and treatment, and has made a huge contribution to the global COVID-19 prevention and treatment. We have provided more than 200 million doses of vaccines. Many countries such as Brazil, Chile and Indonesia have seen China's vaccines play a very important role.
Of course, I also have such an observation. It has shown the efficiency of our vaccine in clinical trials, and it has shown better efficiency than clinical trials in the real-world application process.
I think it can be explained academically, that is, the inactivated vaccine we use not only contains S protein, but vaccines from other countries in the world only contain S protein, and the N protein, M protein, and all other proteins of our entire virus are contained in it. In this inactivated vaccine, the S protein mutates quickly, but other antigens are very conservative, so we may have its uniqueness.
The difference in the protection rate of various new crown vaccines in various countries is mainly in mild cases, and the overall public health effects are similar.
Shao Yiming, a researcher at the Chinese Center for Disease Control and Prevention and a member of the Vaccine R&D Expert Team of the Scientific Research Group:
I think it is more certain that it exists, but we have seen that in the case of insufficient supply of vaccines, any kind of vaccine, we say whether it is Developed and developed by developed countries or developing countries, it is very effective for prevention and control.
We have also observed that in clinical trials, some vaccines, such as mRNA vaccines, have higher protection rates, but the difference in protection rates we are talking about is mainly for mild cases.
We have also observed that all kinds of vaccines have a protection rate of more than 80% for severe illnesses, such as hospitalized cases, those entering the ICU, or death cases. The difference rate is not large, that is, the existing vaccines in various countries are publicly available. The role of hygiene is very similar.